探讨帕金森病中叉头盒A1的表达及意义
Exploring the Expression and Significance of Fork Head Box A1 in Parkinson’s Disease
DOI: 10.12677/acm.2025.152461, PDF,    科研立项经费支持
作者: 赵美丽, 卓 娜：内蒙古医科大学包头临床学院，内蒙古 包头；刘佳慧*：包头市中心医院神经内科，内蒙古 包头
关键词: 叉头盒蛋白A1；帕金森；中脑；多巴胺；FOXA1； Parkinson； Midbrain； Dopamine
摘要: 帕金森病(Parkinson’s disease, PD)是最常见的神经变性运动障碍，累及全球数百万成人。目前PD的病因尚未完全清楚，可能与遗传和环境因素有关，还与氧化应激、神经炎症、免疫异常等有关。目前针对PD缺乏可靠的临床诊断标志物和有效的诊断措施，现有的诊治手段不能延缓疾病的进展。叉头盒A1 (Fork Head Box A1, FOXA1)在中枢神经系统中起重要作用，其缺失可导致酪氨酸羟化酶下调，直接影响多巴胺的合成，从而导致PD，故它可能是PD的潜在治疗靶点，为此，本文将论述FOXA1在帕金森病当中的表达及其可能的致病机制，以期为该疾病的诊断和后期治疗提供借鉴。
Abstract: Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, affecting millions of adults worldwide. At present, the etiology of PD is not fully understood, and it may be related to genetic and environmental factors, as well as oxidative stress, neuroinflammation, and immune abnormalities. At present, there is a lack of reliable clinical diagnostic markers and effective diagnostic measures for PD, and the existing diagnosis and treatment methods cannot delay the progression of the disease. Fork head box A1 (FOXA1) plays an important role in the central nervous system, and its deletion can lead to down-regulation of tyrosine hydroxylase, which directly affects the synthesis of dopamine, resulting in PD, so it may be a potential therapeutic target for PD. Therefore, this article will discuss the expression of FOXA1 in Parkinson’s disease and its possible pathogenic mechanism, in order to provide reference for the diagnosis and later treatment of this disease.
文章引用：赵美丽, 刘佳慧, 卓娜. 探讨帕金森病中叉头盒A1的表达及意义[J]. 临床医学进展, 2025, 15(2): 1191-1196. https://doi.org/10.12677/acm.2025.152461

参考文献

[1] Wei, Z., Li, X., Li, X., Liu, Q. and Cheng, Y. (2018) Oxidative Stress in Parkinson’s Disease: A Systematic Review and Meta-analysis. Frontiers in Molecular Neuroscience, 11, Article 236. [Google Scholar] [CrossRef] [PubMed]
[2] Armstrong, M.J. and Okun, M.S. (2020) Diagnosis and Treatment of Parkinson Disease: A Review. JAMA, 323, 548-560. [Google Scholar] [CrossRef] [PubMed]
[3] Aarsland, D., Batzu, L., Halliday, G.M., Geurtsen, G.J., Ballard, C., Ray Chaudhuri, K., et al. (2021) Parkinson Disease-Associated Cognitive Impairment. Nature Reviews Disease Primers, 7, Article No. 47. [Google Scholar] [CrossRef] [PubMed]
[4] Chen, X., Hu, Y., Cao, Z., Liu, Q. and Cheng, Y. (2018) Cerebrospinal Fluid Inflammatory Cytokine Aberrations in Alzheimer’s Disease, Parkinson’s Disease and Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 9, 2122. [Google Scholar] [CrossRef] [PubMed]
[5] De Virgilio, A., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M.I., Gallo, A., et al. (2016) Parkinson’s Disease: Autoimmunity and Neuroinflammation. Autoimmunity Reviews, 15, 1005-1011. [Google Scholar] [CrossRef] [PubMed]
[6] Yang, X., Zhu, Z., Ding, X., Wang, X., Cui, G., Hua, F., et al. (2018) CaMKII Inhibition Ameliorated Levodopa-Induced Dyskinesia by Downregulating Tyrosine Hydroxylase Activity in an Experimental Model of Parkinson’s Disease. Brain Research, 1687, 66-73. [Google Scholar] [CrossRef] [PubMed]
[7] Lai, E., Prezioso, V.R., Smith, E., Litvin, O., Costa, R.H. and Darnell, J.E. (1990) HNF-3A, a Hepatocyte-Enriched Transcription Factor of Novel Structure Is Regulated Transcriptionally. Genes & Development, 4, 1427-1436. [Google Scholar] [CrossRef] [PubMed]
[8] Kaestner, K.H., Knöchel, W. and Martínez, D.E. (2000) Unified Nomenclature for the Winged Helix/Forkhead Transcription Factors. Genes & Development, 14, 142-146. [Google Scholar] [CrossRef] 
[9] Reizel, Y., Morgan, A., Gao, L., Schug, J., Mukherjee, S., García, M.F., et al. (2021) FoxA-Dependent Demethylation of DNA Initiates Epigenetic Memory of Cellular Identity. Developmental Cell, 56, 602-612.e4. [Google Scholar] [CrossRef] [PubMed]
[10] Gao, B., Xie, W., Wu, X., Wang, L. and Guo, J. (2020) Functionally Analyzing the Important Roles of Hepatocyte Nuclear Factor 3 (FoxA) in Tumorigenesis. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1873, Article ID: 188365. [Google Scholar] [CrossRef] [PubMed]
[11] Kaestner, K.H. (2000) The Hepatocyte Nuclear Factor 3 (HNF3 or FoxA) Family in Metabolism. Trends in Endocrinology & Metabolism, 11, 281-285. [Google Scholar] [CrossRef] [PubMed]
[12] Friedman, J.R. and Kaestner, K.H. (2006) The FoxA Family of Transcription Factors in Development and Metabolism. Cellular and Molecular Life Sciences, 63, 2317-2328. [Google Scholar] [CrossRef] [PubMed]
[13] Reizel, Y., Morgan, A., Gao, L., Lan, Y., Manduchi, E., Waite, E.L., et al. (2020) Collapse of the Hepatic Gene Regulatory Network in the Absence of FoxA Factors. Genes & Development, 34, 1039-1050. [Google Scholar] [CrossRef] [PubMed]
[14] Heslop, J.A. and Duncan, S.A. (2020) FoxA Factors: The Chromatin Key and Doorstop Essential for Liver Development and Function. Genes & Development, 34, 1003-1004. [Google Scholar] [CrossRef] [PubMed]
[15] Ferri, A.L.M., Lin, W., Mavromatakis, Y.E., Wang, J.C., Sasaki, H., Whitsett, J.A., et al. (2007) Foxa1 and Foxa2 Regulate Multiple Phases of Midbrain Dopaminergic Neuron Development in a Dosage-Dependent Manner. Development, 134, 2761-2769. [Google Scholar] [CrossRef] [PubMed]
[16] Yi, S., He, X., Rhee, Y., Park, C., Takizawa, T., Nakashima, K., et al. (2014) Foxa2 Acts as a Co-Activator Potentiating Expression of the Nurr1-Induced DA Phenotype via Epigenetic Regulation. Development, 141, 761-772. [Google Scholar] [CrossRef] [PubMed]
[17] Nelson, A.B. and Kreitzer, A.C. (2014) Reassessing Models of Basal Ganglia Function and Dysfunction. Annual Review of Neuroscience, 37, 117-135. [Google Scholar] [CrossRef] [PubMed]
[18] Hamani, C. (2004) The Subthalamic Nucleus in the Context of Movement Disorders. Brain, 127, 4-20. [Google Scholar] [CrossRef] [PubMed]
[19] Mink, J.W. (2003) The Basal Ganglia and Involuntary Movements: Impaired Inhibition of Competing Motor Patterns. Archives of Neurology, 60, 1365-1368. [Google Scholar] [CrossRef] [PubMed]
[20] Guridi, J. and Obeso, J.A. (2001) The Subthalamic Nucleus, Hemiballismus and Parkinson’s Disease: Reappraisal of a Neurosurgical Dogma. Brain, 124, 5-19. [Google Scholar] [CrossRef] [PubMed]
[21] Rossant, J. (2014) Genes for Regeneration. eLife, 3, Article e02517. [Google Scholar] [CrossRef] [PubMed]
[22] Metzakopian, E., Bouhali, K., Alvarez-Saavedra, M., Whitsett, J.A., Picketts, D.J. and Ang, S. (2015) Genome-Wide Characterisation of Foxa1 Binding Sites Reveals Several Mechanisms for Regulating Neuronal Differentiation in Midbrain Dopamine Cells. Development, 142, 1315-1324. [Google Scholar] [CrossRef] [PubMed]
[23] Lin, W., Metzakopian, E., Mavromatakis, Y.E., Gao, N., Balaskas, N., Sasaki, H., et al. (2009) Foxa1 and Foxa2 Function Both Upstream of and Cooperatively with Lmx1a and Lmx1b in a Feedforward Loop Promoting Mesodiencephalic Dopaminergic Neuron Development. Developmental Biology, 333, 386-396. [Google Scholar] [CrossRef] [PubMed]
[24] Pristerà, A., Lin, W., Kaufmann, A., Brimblecombe, K.R., Threlfell, S., Dodson, P.D., et al. (2015) Transcription Factors FOXA1 and FOXA2 Maintain Dopaminergic Neuronal Properties and Control Feeding Behavior in Adult Mice. Proceedings of the National Academy of Sciences of the United States of America, 112, E4929-E4938. [Google Scholar] [CrossRef] [PubMed]
[25] Stott, S.R.W., Metzakopian, E., Lin, W., Kaestner, K.H., Hen, R. and Ang, S. (2013) Foxa1 and Foxa2 Are Required for the Maintenance of Dopaminergic Properties in Ventral Midbrain Neurons at Late Embryonic Stages. The Journal of Neuroscience, 33, 8022-8034. [Google Scholar] [CrossRef] [PubMed]
[26] Domanskyi, A., Alter, H., Vogt, M.A., Gass, P. and Vinnikov, I.A. (2014) Transcription factors Foxa1 and Foxa2 are required for adult dopamine neurons maintenance. Frontiers in Cellular Neuroscience, 8, Article 275. [Google Scholar] [CrossRef] [PubMed]
[27] Benabid, A.L., Chabardes, S., Mitrofanis, J. and Pollak, P. (2009) Deep Brain Stimulation of the Subthalamic Nucleus for the Treatment of Parkinson’s Disease. The Lancet Neurology, 8, 67-81. [Google Scholar] [CrossRef] [PubMed]
[28] Gasser, E., Johannssen, H.C., Rülicke, T., Zeilhofer, H.U. and Stoffel, M. (2016) Foxa1 Is Essential for Development and Functional Integrity of the Subthalamic Nucleus. Scientific Reports, 6, Article No. 38611. [Google Scholar] [CrossRef] [PubMed]
[29] Liang, T., Zhao, P., Zhang, X., Han, X., Hong, B., Kong, L., et al. (2022) FOXA1 Transcription Activates TFF1 to Reduce 6-OHDA-Induced Dopaminergic Neuron Damage. Experimental and Therapeutic Medicine, 23, Article No. 372. [Google Scholar] [CrossRef] [PubMed]
[30] Li, B., An, D. and Zhu, S. (2022) PBX1 Attenuates 6-Ohda-Induced Oxidative Stress and Apoptosis and Affects PINK1/PARKIN Expression in Dopaminergic Neurons via FOXA1. Cytotechnology, 74, 217-229. [Google Scholar] [CrossRef] [PubMed]
[31] Verma, A., Kommaddi, R.P., Gnanabharathi, B., Hirsch, E.C. and Ravindranath, V. (2023) Genes Critical for Development and Differentiation of Dopaminergic Neurons Are Downregulated in Parkinson’s Disease. Journal of Neural Transmission, 130, 495-512. [Google Scholar] [CrossRef] [PubMed]
[32] Rai, S.N., Dilnashin, H., Birla, H., Singh, S.S., Zahra, W., Rathore, A.S., et al. (2019) The Role of PI3K/Akt and ERK in Neurodegenerative Disorders. Neurotoxicity Research, 35, 775-795. [Google Scholar] [CrossRef] [PubMed]

为你推荐